Status:
RECRUITING
Stem Cell Applications in Biliary Atresia Patients
Lead Sponsor:
Necmi Kadıoğlu Hospital
Conditions:
Biliary Atresia
Fibrosis, Liver
Eligibility:
All Genders
2-18 years
Phase:
NA
Brief Summary
Recently, mesenchymal stem cell (MSC) transplantation has emerged as a promising treatment for liver cirrhosis in adults. Additionally, bone marrow-derived stem cell transplantation has shown success ...
Detailed Description
Biliary atresia (BA) is the most common cause of chronic cholestasis in neonates and accounts for at least 50% of pediatric liver transplants. The incidence of BA is estimated to range from 1:5000 to ...
Eligibility Criteria
Inclusion
- Infants were diagnosed with liver cirrhosis due to biliary atresia following Kasai's operation.
- The patients two months old or older and exhibited signs of cirrhosis after the procedure, including hepatomegaly, congestive splenomegaly, elevated liver enzymes, esophageal varices (confirmed by endoscopy), and cirrhosis (confirmed by liver biopsy).
Exclusion
- Epilepsy
- Neurological disorders
- Coagulation disorders
- Diabetes
- Syndromic type biliary atresia
- Allergies to anesthetic agents
- Severe health conditions such as cancer or failure of the heart, lungs, liver, or kidneys, active infections, and severe psychiatric disorders.
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06564740
Start Date
June 1 2024
End Date
June 1 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Esenyurt State Hospital
Istanbul, Istanbul, Turkey (Türkiye), 34340